Navigation Links
Alexza Receives Complete Response Letter for Adasuve™ NDA
Date:5/3/2012

gram, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a CRL from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010, a REMS guidance meeting with the FDA in April 2011, and the ADASUVE NDA was resubmitted in August 2011.  In December 2011, the ADASUVE NDA was the subject of an advisory committee meeting.  In January 2012, Alexza received notice of a 90-day extension of the PDUFA goal date, from February 4, 2012 to May 4, 2012.  In May 2012, Alexza received a second CRL outlining manufacturing deficiencies.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer Internacional, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011. 

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement
This news release and the planned conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certai
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SOUTHAMPTON , England ... Ltd (ASX: PXS) and UK biotechnology company Synairgen plc (LSE: ... to develop a selective inhibitor to the lysyl oxidase type ... pulmonary fibrosis (IPF). IPF affects in the ... expected to produce global revenues in excess of $1.1 billion ...
(Date:8/4/2015)... -- On August 3, 2015, a press conference on anti-virus ... donation ceremony of a million masks by Wuhan Longfeixiang Technology ... . Wuhan Longfeixiang Technology ... Hubei Longfeixiang Industrial Group, which has successfully developed the ... anti-pollution mask, filling the global gap for masks of ...
(Date:8/4/2015)... ALGONQUIN, Ill. , Aug. 4, 2015 /PRNewswire/ ... of dental supplies and equipment, today announced the ... of Medical Products Laboratories, Inc. ("MPL PDCMD"). MPL ... materials used in preventive and restorative dental procedures. ... strategic expansion of our business in attractive, high-growth ...
Breaking Medicine Technology:Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 2Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 3Young Innovations Announces Acquisition of Medical Products Laboratories' Professional Dental Contract Manufacturing Division 2
... Calif., Sept. 21 VIVUS, Inc. (Nasdaq: ... two-year study of QNEXA® (phentermine/topiramate) Controlled Release Capsules, an ... affects approximately one-third of adult Americans. ... 52-week extension study for a subset of patients who ...
... the GRACE ( G ender, R ace A ... published in the September 21st issue of the Annals ... treatment-experienced adult women with HIV-1 to examine gender differences in ... a division of Centocor Ortho Biotech Services, LLC, the GRACE ...
Cached Medicine Technology:New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 2New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 4New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 5New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 6Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 2Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 3Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 4Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 5Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 6Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 7Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 8
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... it has joined the American Association of Tissue Banks (AATB) as an Affiliate ... its mission “to honor donors, and to save and improve lives by promoting ...
(Date:8/4/2015)... ... August 04, 2015 , ... Wimbledon Health Partners ... and NCV testing, announced their collegiate division, Wimbledon U , continues to ... one program at a time. , “Wimbledon U welcomes the eight ...
(Date:8/4/2015)... ... , ... Angelina Jolie is in it at age 39. “It” is menopause, ... Angela DeRosa, DO, MBA, CPE aka “Dr. Hot Flash,” arguably the Southwest’s leading ... menopause. , Myth #1: Menopause only affects old ladies. – Menopause can affect ...
(Date:8/4/2015)... ... August 04, 2015 , ... Seedstock’s ... for Nov. 3 – 4, 2015, at UC San Diego, will explore innovations ... improve food access, and manage resources efficiently against the dueling backdrop of a ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... 24/7 ... County, Los Angeles, Riverside, and San Bernardino, today announced that the U.S. Department of ... indicate that 24/7 Care At Home’s agency is well on the path to meeting ...
Breaking Medicine News(10 mins):Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3
... Potter star Emma Watson was amazed to see steamy shots ... ,Watson was surprised that she realised how handsome Radcliffe is, ... and I was like, 'Hey'... (It's) the first time I've ... quoted her, as saying. ,However, she said that ...
... the parts of the brain that are involved with ... for treating depression or post traumatic stress disorder, ... concept of memory suppression has been a controversial one ... neuroscientists used brain scans to show that volunteers who ...
... industry charter to keep ultra thin models off catwalks, ... May , when France elected a new government, industry ... fashion, leaders of both France's powerful couture world and ... by the Health Ministry in January amid mounting world ...
... health officials of America, doctors who look after animals ... scares . , Urging veterinarians to work ... contagious diseases, Dr. Julie Gerberding, director of the Atlanta-based ... quoted: "Thirteen out of the last 14 new infectious ...
... US teenagers giving birth has sunk to a record low, with ... report out this week . ,After rising in the ... dropped steadily in the following 15 years, reaching a record low ... in 1991, the report said. ,The birth rate among ...
... her family so much that they have now playfully nicknamed her ... America's Parade magazine that her kids are constantly making fun of ... in and out of the car. ,"Dylan and Carys ... jumping outside. I always think something could happen to them," Contactmusic ...
Cached Medicine News:Health News:Research into Suppressed Memories Could Help Treatment for Depression 2Health News:No Progress in France on 'skinny Model' Charter 2Health News:Vets To Team Up With Human Health Specialists 2
... Human Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) ... liver, which specifically binds and modulates the ... role of IGFBP-1 has not been completely ... suggests that IGFBP-1 may be involved in ...
... in the adrenal gland and gonads, is ... estrone, both of which may be subsequently ... androgenic activity, estimated at ~(less than or ... serum androstenedione levels often exceed testosterone in ...
... II (IGF-II) is a 7.5 kDa peptide which ... postulated to have mitogenic and metabolic actions involved ... mediated by binding to target cell receptors. IGF-II ... IGF receptor, a monomeric protein which also serves ...
... Pregnancy-associated plasma protein A (PAPP-A) ... PAPP-A is produced in high concentrations ... released into the maternal circulation in ... [1]. PAPP-A is not specific to ...
Medicine Products: